Codexis
An American biotechnology company that engineers enzymes and other biological catalysts for pharmaceutical, nutrition, and industrial applications.
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Codexis is a biotechnology company based in Redwood City, California, specializing in the discovery, engineering, and commercialization of enzymes. Its work sits at the intersection of protein engineering, synthetic biology, biocatalysis, and pharmaceutical manufacturing. Rather than selling a single consumer-facing product, Codexis generally works with pharmaceutical, biotechnology, food, nutrition, and industrial customers to develop enzymes that can make chemical and biological processes more selective, efficient, or scalable. The company was incorporated in 2002 and built its business around directed evolution and related protein-engineering methods. In this approach, researchers alter genes encoding proteins, produce many enzyme variants, and screen those variants for useful characteristics such as reaction speed, selectivity, stability, or tolerance to manufacturing conditions. Codexis has combined this laboratory process with computational tools, machine learning, and high-throughput experimentation through its CodeEvolver platform. The objective is to shorten the path from an initial biological catalyst to an enzyme suitable for commercial or therapeutic use. Codexis first became especially visible through pharmaceutical applications. The company received a U.S. Environmental Protection Agency Presidential Green Chemistry Challenge Award in 2006 for work involving an intermediate used in the manufacture of atorvastatin, commonly known by the brand name Lipitor. In 2010, it received a second award for work with Merck on a manufacturing step related to sitagliptin, the active ingredient in Januvia. These projects illustrated the potential of engineered enzymes to replace or improve conventional chemical reactions in pharmaceutical production. The company became a public company in April 2010 through a Nasdaq listing. Later that year, it acquired Maxygen’s MolecularBreeding technology portfolio, adding intellectual property and technical capabilities connected with protein engineering. Codexis has continued to pursue a partnership-based model in which it collaborates with larger pharmaceutical, nutrition, and biotechnology companies while also developing proprietary enzyme and biotherapeutic programs. Its nutrition and food-related activities expanded through collaborations announced in 2017. Codexis entered a research and development partnership with Tate & Lyle focused on new ingredients and also announced a collaboration with Nestlé involving enzymes for metabolic-disorder applications. In the biotherapeutics area, Codexis developed a recombinant phenylalanine ammonia-lyase enzyme intended to provide a functional substitute for phenylalanine hydroxylase in people with phenylketonuria. The program was subsequently in-licensed by Nestlé Health Science. Codexis has also applied its platform to emerging biotechnology infrastructure. In 2020, Takeda Pharmaceutical announced a collaboration with Codexis to research and create gene-therapy technologies for rare diseases, including lysosomal storage disorders. The same year, Codexis announced a partnership with Molecular Assemblies to engineer enzymes for enzymatic DNA synthesis. These activities broadened the company’s role beyond conventional pharmaceutical-process development into biotherapeutics and biological manufacturing technologies. Codexis’s positioning is therefore that of a technology partner and enzyme-platform company. Its commercial value comes from solving difficult reaction and manufacturing problems with engineered proteins, rather than from operating primarily as a branded consumer business. The company’s public identity remains closely associated with CodeEvolver, directed evolution, biocatalysis, and collaborations intended to improve pharmaceutical, nutrition, and life-science production processes.
History
Codexis was incorporated in 2002 in the United States and developed as a specialist biotechnology company focused on protein engineering and enzyme development. Its central scientific approach is directed evolution: researchers modify genes that encode proteins, generate libraries of enzyme variants, and test those variants to identify improved performance. Desired characteristics can include higher catalytic activity, greater selectivity, improved stability, or the ability to function under conditions required for industrial production. Codexis has supplemented this experimental process with computational analysis, machine learning, and high-throughput screening through its CodeEvolver platform. The company’s early commercial identity was strongly connected to pharmaceutical manufacturing. In 2006, Codexis received a U.S. Environmental Protection Agency Presidential Green Chemistry Challenge Award for work on a building block used in the manufacture of atorvastatin, the active pharmaceutical ingredient associated with Lipitor. The recognition reflected the use of engineered biological catalysts in a process that could offer advantages over purely conventional chemical synthesis. In 2010, Codexis received a second Presidential Green Chemistry Challenge Award for work conducted with Merck on the active ingredient in Januvia, sitagliptin. Together, these awards helped establish the company’s reputation in industrial biocatalysis and pharmaceutical process development. Codexis became publicly traded on Nasdaq in April 2010. In October of the same year, it acquired Maxygen’s MolecularBreeding technology portfolio. The transaction expanded Codexis’s access to protein-engineering technologies and strengthened the technical foundation underlying its enzyme-discovery activities. The company’s operating model has generally emphasized collaborations and licensing relationships with larger pharmaceutical, food, nutrition, and biotechnology organizations, allowing its platform to be applied to partner-specific manufacturing or therapeutic challenges. In 2017, Codexis broadened its activity in nutrition and biotherapeutics. It entered a research and development partnership with Tate & Lyle to explore new ingredients and announced a collaboration with Nestlé concerning enzymes for metabolic disorders. During the same period, Codexis developed a recombinant phenylalanine ammonia-lyase enzyme intended to act as a functional substitute for phenylalanine hydroxylase in people with phenylketonuria. The program was in-licensed by Nestlé Health Science, illustrating how Codexis could originate or improve biological candidates while relying on a larger healthcare organization for later development or commercialization. The company continued applying its enzyme-engineering capabilities to life-science technologies in 2020. Takeda Pharmaceutical announced a collaboration with Codexis to research and create gene-therapy technologies for rare diseases, including lysosomal storage disorders. Codexis also partnered with Molecular Assemblies to engineer enzymes for DNA synthesis. This work placed the company within a broader movement toward enzymatic methods for biological manufacturing and nucleic-acid production. Codexis’s business scope consequently extends across pharmaceutical process chemistry, food and nutrition ingredients, therapeutic enzymes, gene-therapy research, and biotechnology tools. Its platform is not primarily a consumer brand; it is a technical infrastructure and partnering business whose products may be incorporated into another company’s manufacturing process or therapeutic program. The company’s enduring differentiation is its combination of directed evolution, protein engineering, screening, and computational methods aimed at turning naturally occurring or laboratory-designed proteins into commercially useful catalysts. Codexis remains headquartered in Redwood City, California, and is listed on Nasdaq under the symbol CDXS.
- 2020
Expansion into gene therapy and DNA synthesis
[1]Codexis announced collaborations with Takeda on rare-disease gene therapies and with Molecular Assemblies on enzymatic DNA synthesis.
- 2017
Expansion into nutrition and therapeutic-enzyme collaborations
[1]Codexis announced partnerships with Tate & Lyle and Nestlé and developed a recombinant phenylalanine ammonia-lyase program for phenylketonuria.
- 2010
Nasdaq listing and MolecularBreeding portfolio acquisition
[1]Codexis became publicly traded in April and acquired Maxygen’s MolecularBreeding technology portfolio in October.
- 2010
Second Presidential Green Chemistry Challenge Award
[1]Codexis and Merck received recognition for work involving the active ingredient in Januvia.
- 2006
First Presidential Green Chemistry Challenge Award
[1]The U.S. Environmental Protection Agency recognized Codexis for work on a building block used in atorvastatin manufacturing.
- 2002
Codexis is incorporated
[1]Codexis was incorporated in the United States and began developing enzyme and protein-engineering capabilities.
Products and positioning
A technology and collaboration partner providing engineered enzymes, biocatalysts, and protein-engineering capabilities for pharmaceutical, nutrition, biotechnology, and industrial applications.
Protein-engineering platform
CodeEvolver
CodeEvolver is Codexis’s protein-engineering platform. It combines directed evolution, high-throughput experimentation, screening, computational analysis, and machine-learning methods to identify protein-sequence changes associated with useful enzyme characteristics. The platform is used to develop catalysts for pharmaceutical manufacturing, nutrition, biotechnology, and other applications rather than functioning as a conventional standalone consumer product.
Pharmaceutical manufacturing biocatalysts
Engineered pharmaceutical enzymes
Codexis develops engineered enzymes for pharmaceutical-process chemistry. These catalysts are designed to perform particular transformations with improved selectivity, efficiency, or manufacturability. The company’s work on atorvastatin and sitagliptin manufacturing helped demonstrate how engineered enzymes could be integrated into the production of active pharmaceutical ingredients and related intermediates.
Therapeutic enzyme · 2017
Recombinant phenylalanine ammonia-lyase
Codexis developed a recombinant phenylalanine ammonia-lyase intended to provide a functional substitute for phenylalanine hydroxylase in people with phenylketonuria. The program was in-licensed by Nestlé Health Science, making it an example of Codexis’s role in originating and engineering therapeutic enzyme candidates for subsequent development by a healthcare partner.
Biotechnology enzymes · 2020
Enzymes for DNA synthesis
Through its collaboration with Molecular Assemblies, Codexis applies enzyme-engineering expertise to DNA synthesis. The objective is to create or improve biological catalysts that can support enzymatic approaches to producing DNA, an area relevant to synthetic biology, research tools, and future biotechnology manufacturing.
Marketing campaigns
- 2017Tate & Lyle ingredient-development partnership
Global nutrition and food ingredients
Codexis entered a research and development partnership with Tate & Lyle to investigate new ingredients produced with enzyme-engineering capabilities.
- 2017Nestlé metabolic-disorder enzyme collaboration
Global healthcare and nutrition
Codexis collaborated with Nestlé on enzyme applications related to metabolic disorders and developed a recombinant phenylalanine ammonia-lyase program for phenylketonuria.
Outcome. Nestlé Health Science in-licensed the phenylalanine ammonia-lyase program.
- 2010Merck sitagliptin biocatalysis collaboration
United States · Pharmaceutical manufacturing
Codexis worked with Merck on an enzyme-enabled manufacturing process associated with sitagliptin, the active ingredient in Januvia.
Outcome. The collaboration received a second Presidential Green Chemistry Challenge Award for Codexis-related work.
- 2006Green chemistry pharmaceutical manufacturing program
United States · Pharmaceutical manufacturing
Codexis promoted the use of engineered enzymes in pharmaceutical production through work on a building block used to manufacture atorvastatin.
Outcome. The work received a U.S. EPA Presidential Green Chemistry Challenge Award.
Brand decisions
2020
Extend enzyme engineering into gene therapy and DNA synthesisStrategyBackground
Codexis pursued applications for engineered enzymes in newer biotechnology workflows.
Action taken
The company announced collaborations with Takeda on rare-disease gene therapies and with Molecular Assemblies on enzymatic DNA synthesis.
Aftermath
These collaborations expanded the company’s stated application areas into gene-therapy research and synthetic-biology infrastructure.
2017
Expand from pharmaceutical biocatalysis into nutrition and biotherapeuticsStrategyBackground
Codexis applied its enzyme-engineering platform to markets beyond pharmaceutical process chemistry.
Action taken
The company announced partnerships with Tate & Lyle and Nestlé and advanced a recombinant phenylalanine ammonia-lyase program for phenylketonuria.
Aftermath
The initiatives broadened Codexis’s collaboration portfolio into food ingredients, metabolic disorders, and therapeutic enzymes.
2010
Acquire Maxygen’s MolecularBreeding technology portfolioM&ABackground
Codexis sought to expand the intellectual-property and technical base supporting its protein-engineering activities.
Action taken
The company acquired Maxygen’s MolecularBreeding technology portfolio in October 2010.
Aftermath
The acquisition added protein-engineering technology to Codexis’s platform following its public listing earlier that year.
Recent events
- 2020
Takeda and Codexis announce rare-disease gene-therapy collaboration[1]
Other
Takeda announced a collaboration with Codexis to research and create gene-therapy technologies for rare diseases, including lysosomal storage disorders.
- 2020
Codexis partners with Molecular Assemblies on enzymatic DNA synthesis[1]
Other
Codexis and Molecular Assemblies announced a partnership to engineer enzymes for DNA synthesis.
- 2017
Codexis and Tate & Lyle announce nutrition-ingredient research partnership[1]
Other
The companies entered a research and development partnership focused on producing new ingredients using Codexis’s enzyme-engineering capabilities.
- 2017
Codexis collaborates with Nestlé on enzymes for metabolic disorders[1]
Other
Codexis announced a collaboration with Nestlé involving enzyme applications for metabolic-disorder programs.
- 2017
Codexis develops a recombinant enzyme for phenylketonuria[1]
Product launch · Other
Codexis developed a recombinant phenylalanine ammonia-lyase intended to substitute for the phenylalanine hydroxylase activity lacking in people with phenylketonuria. The program was later in-licensed by Nestlé Health Science.
- 2010
Codexis becomes a publicly traded company on Nasdaq[1]
Other
Codexis completed its public-market listing in April 2010, giving the enzyme-engineering company access to public equity markets.
- 2010
Codexis acquires Maxygen’s MolecularBreeding technology portfolio[1]
M&A
Codexis acquired the MolecularBreeding technology portfolio from Maxygen, expanding its protein-engineering technology base.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/codexis · Editorial policy · How profiles are compiled